Day: August 21, 2025
MELBOURNE, Australia and INDIANAPOLIS, Aug. 21, 2025 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces its financial results for the half-year ended 30 June 2025. All figures are in USD unless stated otherwise.
H1 2025 key results1
Group performance2: Reflects strategic investment for long-term value creationRevenue of $390.4 million, up by 63%3 and on track to meet full year guidance4.
Group gross profit margin of 53% reflects product mix change to include third-party RLS sales. Illuccix® margin remains stable.
Adjusted EBITDA5 of $21.1 million, reflective of increased operating expenditure driven by strategic acquisitions, investment in commercial infrastructure, and research and development (R&D) investment.
$81.6 million invested into R&D, a 47% increase...